Xenetic Biosciences Inc Dossier
Qualitative Analysis
Business overview
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company focused on the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics. The company's primary scientific focus is its proprietary Deoxyribonuclease (DNase) platform technology, which is designed to target neutrophil extracellular traps (NETs). NETs are web-like structures composed of extracellular chromatin that are expelled by activated neutrophils and have been linked to tumor progression, metastasis, inflammation, and resistance to standard cancer therapies, including immunotherapies, chemotherapy, and radiotherapy. By systemically administering DNase, Xenetic aims to break down these NETs, improve the tumor microenvironment, and enhance the efficacy of existing cancer treatments. The company is currently focused on advancing its systemic DNase program into Phase 1 clinical development as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Additionally, Xenetic has historically developed the PolyXen platform, a patent-protected technology for biologics drug delivery that is sublicensed to Takeda Pharmaceuticals Co. Ltd. for the treatment of coagulation disorders, generating recurring royalty revenues.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the development of the DNase I platform, which targets Neutrophil Extracellular Traps (NETs) to improve the efficacy of cancer therapies.
Expected impact: Aims to improve outcomes of existing treatments (immunotherapies, chemotherapies) by targeting neutrophil extracellular traps (NETs) that contribute to treatment resistance.
A formal strategic review process conducted by the Board and a special independent committee to explore options to maximize shareholder value.
Expected impact: Potential sale of the company, asset divestitures, or a business combination/reverse merger.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
PeriNess leads the regulatory approval, operational execution, and management of exploratory investigator-initiated studies of recombinant DNase in Israel [2.4.2].
Terms: PeriNess manages and executes the clinical trials under a Clinical Trial Services Agreement.
Collaborating with the lab of Dr. Alexey Stepanov to advance the development of the combination of systemic DNase I and CAR T-cell therapies.
Terms: Extended the agreement with additional funding of up to approximately $400,000.
Provides recurring royalty revenue from the PolyXen platform technology, which helps fund the company's internal DNase development.
Terms: Generated $806,923 in royalty revenue for the three months ended March 31, 2026 (a 36% increase year-over-year).